CDNA
Price
$18.48
Change
-$0.01 (-0.05%)
Updated
Apr 25 closing price
Capitalization
548.33M
2 days until earnings call
SRTS
Price
$4.74
Change
+$0.06 (+1.28%)
Updated
Apr 25 closing price
Capitalization
61.97M
3 days until earnings call
Ad is loading...

CDNA vs SRTS

Header iconCDNA vs SRTS Comparison
Open Charts CDNA vs SRTSBanner chart's image
CareDx
Price$18.48
Change-$0.01 (-0.05%)
Volume$362.62K
Capitalization548.33M
Sensus Healthcare
Price$4.74
Change+$0.06 (+1.28%)
Volume$27.69K
Capitalization61.97M
CDNA vs SRTS Comparison Chart
Loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDNA vs. SRTS commentary
Apr 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a Buy and SRTS is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 28, 2025
Stock price -- (CDNA: $18.48 vs. SRTS: $4.74)
Brand notoriety: CDNA and SRTS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CDNA: 49% vs. SRTS: 18%
Market capitalization -- CDNA: $548.33M vs. SRTS: $61.97M
CDNA [@Medical Specialties] is valued at $548.33M. SRTS’s [@Medical Specialties] market capitalization is $61.97M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 0 FA rating(s) are green whileSRTS’s FA Score has 0 green FA rating(s).

  • CDNA’s FA Score: 0 green, 5 red.
  • SRTS’s FA Score: 0 green, 5 red.
According to our system of comparison, CDNA is a better buy in the long-term than SRTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 3 TA indicator(s) are bullish while SRTS’s TA Score has 3 bullish TA indicator(s).

  • CDNA’s TA Score: 3 bullish, 3 bearish.
  • SRTS’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both CDNA and SRTS are a good buy in the short-term.

Price Growth

CDNA (@Medical Specialties) experienced а +4.88% price change this week, while SRTS (@Medical Specialties) price change was +3.27% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +5.62%. For the same industry, the average monthly price growth was -3.92%, and the average quarterly price growth was -1.88%.

Reported Earning Dates

CDNA is expected to report earnings on Aug 12, 2025.

SRTS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Medical Specialties (+5.62% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDNA($548M) has a higher market cap than SRTS($62M). CDNA YTD gains are higher at: -13.685 vs. SRTS (-31.503). SRTS has higher annual earnings (EBITDA): 79K vs. CDNA (-84.92M). CDNA has more cash in the bank: 235M vs. SRTS (23.1M). SRTS has less debt than CDNA: SRTS (783K) vs CDNA (34.2M). CDNA has higher revenues than SRTS: CDNA (280M) vs SRTS (24.4M).
CDNASRTSCDNA / SRTS
Capitalization548M62M884%
EBITDA-84.92M79K-107,492%
Gain YTD-13.685-31.50343%
P/E RatioN/A126.00-
Revenue280M24.4M1,148%
Total Cash235M23.1M1,017%
Total Debt34.2M783K4,368%
FUNDAMENTALS RATINGS
CDNA vs SRTS: Fundamental Ratings
CDNA
SRTS
OUTLOOK RATING
1..100
2432
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
5260
PRICE GROWTH RATING
1..100
4260
P/E GROWTH RATING
1..100
63100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDNA's Valuation (50) in the Medical Specialties industry is in the same range as SRTS (50). This means that CDNA’s stock grew similarly to SRTS’s over the last 12 months.

SRTS's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as CDNA (100). This means that SRTS’s stock grew similarly to CDNA’s over the last 12 months.

CDNA's SMR Rating (52) in the Medical Specialties industry is in the same range as SRTS (60). This means that CDNA’s stock grew similarly to SRTS’s over the last 12 months.

CDNA's Price Growth Rating (42) in the Medical Specialties industry is in the same range as SRTS (60). This means that CDNA’s stock grew similarly to SRTS’s over the last 12 months.

CDNA's P/E Growth Rating (63) in the Medical Specialties industry is somewhat better than the same rating for SRTS (100). This means that CDNA’s stock grew somewhat faster than SRTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDNASRTS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
71%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
82%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 7 days ago
83%
View a ticker or compare two or three
Ad is loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OXM51.910.57
+1.11%
Oxford Industries
NATH96.040.22
+0.23%
Nathan's Famous
RHP86.31-0.36
-0.42%
Ryman Hospitality Properties
HON199.16-1.58
-0.79%
Honeywell International
PPSI2.75-0.05
-1.79%
Pioneer Power Solutions

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with NTRA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then NTRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-0.05%
NTRA - CDNA
43%
Loosely correlated
-0.45%
MTD - CDNA
42%
Loosely correlated
-1.23%
VCYT - CDNA
42%
Loosely correlated
+0.28%
A - CDNA
37%
Loosely correlated
-0.69%
BLFS - CDNA
37%
Loosely correlated
+0.63%
More

SRTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRTS has been loosely correlated with LUNG. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SRTS jumps, then LUNG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRTS
1D Price
Change %
SRTS100%
+1.28%
LUNG - SRTS
57%
Loosely correlated
+0.58%
VAPO - SRTS
35%
Loosely correlated
N/A
BDX - SRTS
29%
Poorly correlated
+0.31%
CDNA - SRTS
28%
Poorly correlated
-0.05%
MTD - SRTS
28%
Poorly correlated
-1.23%
More